argenx stock rating reiterated at Outperform by RBC on Vyvgart success

RBC Capital reiterated an Outperform rating on argenx SE (ARGX) with an $850 price target, driven by positive Phase III results for its Vyvgart treatment, which demonstrated efficacy across all myasthenia gravis antibody subtypes, including seronegative patients. This clinical validation, combined with the company's robust Q2 2025 earnings beat (EPS $6.32 vs. $3.06 forecast; Revenue $1.74B vs. $876.3M forecast) and strong financial position, underpins confidence in Vyvgart's projected uptake doubling and argenx's extensive pipeline.

Analysis

Argenx SE (ARGX) has received a significant vote of confidence from RBC Capital, which reiterated its Outperform rating and an $850 price target. This outlook is anchored by pivotal Phase III clinical trial results for its key drug, Vyvgart, which demonstrated meaningful efficacy in myasthenia gravis patients across all antibody subtypes, a first for a treatment in this space and a crucial de-risking event. The result is particularly notable as it mitigates concerns from the prior ADAPT trial, which showed a high placebo response. Financially, argenx exhibits exceptional strength, highlighted by a massive second-quarter 2025 earnings beat where EPS of $6.32 more than doubled the $3.06 forecast, and revenue of $1.74 billion nearly doubled the expected $876.3 million. This commercial success is supported by a robust balance sheet with more cash than debt, excellent liquidity, a 21.4% return on assets, and gross profit margins exceeding 52%. The combination of validated clinical superiority, stellar financial execution, and a deep pipeline of 20 late-stage trials underpins RBC's projection that Vyvgart's uptake will double in its approved indications.

Key Decisions for Investors

• Investors could view the confluence of positive Phase III data and a significant earnings beat as a strong validation of the company's clinical and commercial strategy, supporting a bullish thesis on the stock.
• It is crucial to monitor the continued commercial ramp-up of Vyvgart and progress within the 20-trial late-stage pipeline, as sustained execution on these fronts is now paramount to justifying the current valuation.
• Given the extremely positive sentiment and recent outperformance, investors should be aware that expectations are now significantly elevated, making the stock potentially more volatile in response to future clinical or commercial updates.